Generated by All in One SEO v4.9.6.2, this is an llms.txt file, used by LLMs to index the site. # Nura Bio™ Developing neurotherapeutics to halt serious diseases before they progress too far ## Sitemaps - [XML Sitemap](https://nurabio.com/sitemap.xml): Contains all public & indexable URLs for this website. ## Posts - [Nura Bio Completes $73.8M Series B Financing and Advances Pipeline of SARM1 Inhibitors](https://nurabio.com/news/nura-bio-completes-73-8m-series-b-financing-and-advances-pipeline-of-sarm1-inhibitors/) - Nura Bio raises $73.8M Series B to advance SARM1 inhibitors, dosing first ALS patient with NB-4746 and initiating first-in-human study of NB-9402. - [Nura Bio Expands Leadership Team with C-Suite Appointments](https://nurabio.com/news/nura-bio-expands-leadership-team-with-c-suite-appointments/) - Nura Bio announces the appointments of Lahar Mehta, M.D. as Chief Medical Officer, and Scott Greenberg as Chief Business Officer. - [Nura Bio Initiates Phase I Clinical Trial for its Oral, Brain-Penetrant SARM1 Inhibitor, NB-4746](https://nurabio.com/news/nura-bio-initiates-phase-1-clinical-trial-for-its-oral-brain-penetrant-sarm1-inhibitor-nb-4746/) - Nura Bio, Inc. (Nura Bio), a biopharmaceutical company developing neuroprotective, small molecule therapies for the treatment of debilitating neurological diseases, today announced the initiation of the Phase 1 clinical trial of its SARM1 inhibitor, NB-4746. - [Nura Bio reports preclinical data validating a conserved mechanism of inhibition of NAD hydrolases implicated in neurodegeneration in NEURON](https://nurabio.com/news/nura-bio-reports-preclinical-data-validating-a-conserved-mechanism-of-inhibition-of-nad-hydrolases-implicated-in-neurodegeneration-in-neuron/) - Nura Bio Inc., a biopharma company created to discover and develop life-changing neuroprotective drugs, today announced the publication of “Uncompetitive, adduct-forming SARM1 inhibitors are neuroprotective in preclinical models of nerve injury and disease” in NEURON. - [Nura Bio Announces publication of “Structural and Mechanistic Regulation of the Prodegenerative NAD Hydrolase SARM1” in CELL REPORTS](https://nurabio.com/news/nura-bio-announces-publication-of-structural-and-mechanistic-regulation-of-the-prodegenerative-nad-hydrolase-sarm1-in-cell-reports/) - Nura Bio Inc., a biopharma company created to discover and develop life-changing neuroprotective drugs, today announced the publication of “Structural and Mechanistic Regulation of the Prodegenerative NAD Hydrolase SARM1” in CELL REPORTS. The publication by Bratkowski et.al., provides novel structural and mechanistic insights into SARM1’s transition from an autoinhibited to injury-activated, pro-degenerative state. - [Nura Bio Closes Series A Financing with $68 Million in New Funds, Bringing Total Raised to $140+ Million](https://nurabio.com/news/nura-bio-closes-series-a-financing-with-68-million-in-new-funds-bringing-total-raised-to-140-million/) - Nura Bio announces over $140M in Series A financing, completion of Phase 1 study of NB-4746, and appointment of Shilpa Sambashivan, Ph.D. as CEO and Director. - [Nura Bio Launches to Discover and Develop Neuroprotective Drugs, Backed by $73 Million Series A Financing](https://nurabio.com/uncategorized/nura-bio-launches-to-discover-and-develop-neuroprotective-drugs-backed-by-73-million-series-a-financing/) - - Targeting axonal degeneration and neuroinflammation, early hallmarks of several acute and chronic neurological diseases - Financing syndicate led by The Column Group with Samsara BioCapital and Euclidean Capital. - Alpna Seth, PhD, appointed President and CEO - [Nura Bio Closes Series A Financing with $68 Million in New Funds, Bringing Total Raised to $140+ Million](https://nurabio.com/uncategorized/nura-bio-closes-series-a-financing-with-68-million-in-new-funds-bringing-total-raised-to-140-million-2/) - Nura Bio announces over $140M in Series A financing, completion of Phase 1 study of NB-4746, and appointment of Shilpa Sambashivan, Ph.D. as CEO and Director. - [Marc Freeman wins first annual Drs. Ayeez and Shelena Lalji & Family ALS Endowed Award for Innovative Healing](https://nurabio.com/news/marc-freeman-wins-first-annual-drs-ayeez-and-shelena-lalji-family-als-endowed-award-for-innovative-healing/) ## Pages - [Home](https://nurabio.com/) - [News & Literature](https://nurabio.com/news-and-literature/) - [Join Us](https://nurabio.com/join-us/) - [About Us](https://nurabio.com/about-us/) - [Contact](https://nurabio.com/contact/) - [Our Science](https://nurabio.com/our-science/) ## Portfolio Items - [ABE BASSAN](https://nurabio.com/team/abe-bassan/) - [SHILPA SAMBASHIVAN, PhD](https://nurabio.com/team/shilpa-sambashivan/) - [SCOTT GREENBERG](https://nurabio.com/team/scott-greenberg/) - [LAHAR MEHTA, MD](https://nurabio.com/team/lahar-mehta-md/) - [SHILPA SAMBASHIVAN, PhD](https://nurabio.com/team/shilpa-sambashivan-phd/) - [SANJAY KESWANI, MBBS, FRCP](https://nurabio.com/team/sanjay-keswani/) - [JOHN JOSEY, PhD](https://nurabio.com/team/john-josey/) - [MARK GOLDSMITH, MD, PhD](https://nurabio.com/team/mark-goldsmith/) - [STEVE MCKNIGHT, PhD](https://nurabio.com/team/steve-mcknight/) - [MARC FREEMAN, PhD](https://nurabio.com/team/marc-freeman/) - [TIM KUTZKEY, PhD](https://nurabio.com/team/tim-kutzkey/) ## Categories - [Uncategorized](https://nurabio.com/category/uncategorized/) - [News](https://nurabio.com/category/news/) ## Portfolio Categories - [Leadership](https://nurabio.com/team/leadership/) - [Board of Directors](https://nurabio.com/team/board-of-directors/) - [Founders and Advisors](https://nurabio.com/team/founders-and-advisors/)